Article
E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.
Molecular cancer therapeutics - 1 Nov 2016
Watanabe Miyano Saori, Yamamoto Yuji, Kodama Kotaro, Miyajima Yukiko, Mikamoto Masaki, Nakagawa Takayuki, Kuramochi Hiroko, Funasaka Setsuo, Nagao Satoshi, Sugi Naoko Hata, Okamoto Kiyoshi, Minoshima Yukinori, Nakatani Yusuke, Karoji Yuki, Ohashi Isao, Yamane Yoshinobu, Okada Toshimi, Matsushima Tomohiro, Matsui Junji, Iwata Masao, Uenaka Toshimitsu, Tsuruoka Akihiko
Abstract excerpt
The FGFR signaling pathway has a crucial role in proliferation, survival, and migration of cancer cells, tumor angiogenesis, and drug resistance. FGFR genetic abnormalities, such as gene fusion, mutation, and amplification, have been implicated in several types of cancer. Therefore, FGFRs are considered potential targets for cancer therapy. E7090 is an orally available and selective inhibitor of the tyrosine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.